Reducing the Global Impact of Diabetes

Diamune’s cutting-edge and proprietary Fc-fusion protein technology has allowed the development of products that are changing the way diabetes is treated and prevented.

AKS-107 offers a prevention-first approach to type 1 diabetes, intervening at the earliest stage (Stage 1) before the disease commences. AKS-440, a once-weekly basal insulin therapy, transforms type 2 diabetes management by improving convenience and control with fewer injections.